Recently, a phase I clinical trial demonstrated that replication of DNX-2401 in recurrent GBM tumors facilitated tumor cell death and some immunogenic cell death by infiltrating CD8+ T cells and TH cells, lengthening mOS to 13.0 months [75]. The gene discussed is CD8A; the disease is glioblastoma.